CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate (ADC) developed under license from Corbus Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval to initiate a registrational clinical trial for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC). The product previously received Fast Track Designations from the FDA for both head and neck squamous cell carcinoma (HNSCC) and cervical cancer, underscoring its potential to address significant unmet needs in multiple oncology indications.

Regulatory Milestone

Drug Profile & Target Validation

• Target Antigen: Nectin-4, a clinically validated tumor-associated antigen with established therapeutic relevance
• Target Expression Profile:
• Highly expressed in head and neck squamous cell carcinoma (HNSCC), including OPSCC
• Clearly expressed in urothelial carcinoma (validated by enfortumab vedotin approval)
• Significant expression in cervical cancer and other solid tumors
• Technology Platform: Next-generation antibody-drug conjugate (ADC) with optimized drug-to-antibody ratio and linker stability
• Mechanism of Action: Selective delivery of cytotoxic payload to Nectin-4 expressing tumor cells, minimizing off-target toxicity while maximizing anti-tumor efficacy
• Competitive Landscape: Builds upon clinical validation established by enfortumab vedotin (Padcev®) in urothelial carcinoma, but targets different tumor types with high unmet need

Market Opportunity & Clinical Need

Oropharyngeal squamous cell carcinoma represents approximately 60-70% of all head and neck cancers, with incidence rates increasing due to HPV-associated disease. Second-line treatment options remain limited, with response rates typically below 15% and median overall survival of 6-9 months. The global HNSCC market is projected to reach $3.8 billion by 2028, with significant growth potential for targeted therapies addressing refractory disease.

Key unmet needs addressed by CRB-701:

• Limited effective second-line options following platinum-based chemotherapy failure
• Poor prognosis in recurrent/metastatic settings with current standard of care
• Need for targeted approaches leveraging validated tumor antigens with favorable safety profiles
• Opportunity for biomarker-driven therapy based on Nectin-4 expression levels

Strategic Implications

• For CSPC Pharmaceutical: Represents significant milestone in global oncology ambitions and validates international development capabilities beyond traditional Chinese markets
• Partnership Value: Demonstrates successful licensing and development collaboration with U.S.-based Corbus Pharmaceuticals
• Regulatory Strategy: Fast Track Designation provides enhanced FDA interaction and potential for accelerated approval pathways
• Commercial Potential: Success in OPSCC could support rapid expansion into broader HNSCC and cervical cancer indications
• Global Positioning: Positions CSPC as competitive player in next-generation ADC space alongside major pharmaceutical companies

Next Steps

• Trial Design: Phase II/III registrational study evaluating overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in 2L OPSCC
• Patient Selection: Likely to include Nectin-4 expression as enrichment biomarker based on target validation data
• Regulatory Timeline: Target Biologics License Application (BLA) submission by 2028 pending positive trial results
• Combination Strategies: Explore potential combination with immunotherapy agents (PD-1/PD-L1 inhibitors) for enhanced efficacy

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive developments, and market acceptance.-Fineline Info & Tech